Core Scientific, Inc. current report, 15 April 2024

Full document

Core Scientific, Inc. — Form 8-K Summary

Business Context and Reporting Period

Core Scientific, Inc. filed a Form 8-K dated April 15, 2024, under Item 7.01 (Regulation FD Disclosure). The filing concerns the company’s registration of outstanding common stock for resale by certain existing stockholders. It is not a periodic financial report and does not cover a financial reporting period.

Financial Metrics and Capital Structure

  • The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
  • The company will not sell any shares in the registered offering and will not receive proceeds from sales by the selling stockholders.
  • The filing identifies Nasdaq-listed common stock under the symbol CORZ and warrants under CORZW and CORZZ.

Material Changes Versus Prior Period

The filing does not report comparative financial results or a material operating change versus a prior period. The disclosed development is the filing of a Form S-1 registration statement to satisfy registration rights granted to certain existing stockholders.

Guidance, Outlook, Risks, and Unusual Items

  • The Form S-1 had been filed with the SEC but was not yet effective as of the Form 8-K date.
  • The registered securities may not be sold, and offers to buy may not be accepted, before the registration statement becomes effective.
  • The offering is for resale by existing stockholders; it is not a primary capital raise by Core Scientific.
  • The filing includes customary securities-law disclaimers stating that the related press release is not an offer to sell or solicitation to buy securities before applicable registration or qualification.
  • The disclosure was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly stated.

Investor Verification Items

  • Verify whether and when the Form S-1 becomes effective.
  • Review the final prospectus for the identity of selling stockholders and the number of shares registered for resale.
  • Assess potential market overhang and dilution-related effects, although the company will not receive offering proceeds.
  • Confirm any subsequent amendments, selling activity, or changes in the number of registered shares.